HC Wainwright & Co. Downgrades Caribou Biosciences to Neutral

HC Wainwright & Co. analyst Robert Burns has downgraded Caribou Biosciences (NASDAQ: CRBU) from a 'Buy' rating to 'Neutral'. This change reflects a shift in the firm's outlook on the company's performance.